US 12,251,372 B2
Antileishmanial compounds, compositions and use thereof
Scott E. Schaus, Boston, MA (US); Lauren E. Brown, Waltham, MA (US); Mark W. Grinstaff, Brookline, MA (US); Danielle M. Fitzgerald, Boston, MA (US); Diana L Diaz, Brighton, MA (US); John A. Kavouris, Woburn, MA (US); Jair Lage De Siqueira-Neto, San Diego, CA (US); James McKerrow, San Diego, CA (US); and Camila Indiani De Oliveira, Caminho das Árvores Salvador (BA)
Assigned to TRUSTEES OF BOSTON UNIVERSITY; THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and FUNDAÇÄO OSWALDO CRUZ, Rio de Janeiro (BR)
Filed by TRUSTEES OF BOSTON UNIVERSITY, Boston, MA (US); THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US); and FUNDAÇÄO OSWALDO CRUZ, Manguinhos (BR)
Filed on May 25, 2023, as Appl. No. 18/201,938.
Claims priority of provisional application 63/345,662, filed on May 25, 2022.
Prior Publication US 2023/0381142 A1, Nov. 30, 2023
Int. Cl. A61K 31/4162 (2006.01); A61K 9/16 (2006.01); A61K 31/4178 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61P 33/02 (2006.01)
CPC A61K 31/4162 (2013.01) [A61K 9/1647 (2013.01); A61K 31/4178 (2013.01); A61K 31/427 (2013.01); A61K 31/437 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61P 33/02 (2018.01)] 23 Claims
OG exemplary drawing
 
1. A composition comprising:
a. a polymer selected from the group consisting of polycarbonates, polyesters, polyacrylates, polyamides, and copolymers and mixtures thereof; and
b. a compound of Formula (I) or (II):

OG Complex Work Unit Chemistry
wherein:
Y is NR14, CH2, O or S;
R11 is aryl, or heteroaryl, each optionally substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, hydroxyl, alkoxy, alkyl, cycloalkyl, carboxyl, oxo, nitro, amino, alkylamino dialkylamino, carboxy, sulfonyl, sulfonamide, thiol, and cyano, or
R11 is alkyl, or alkenyl, each optionally substituted with 1 or 2 substituents selected independently from the group consisting of halogen, hydroxyl, alkoxy, cycloalkyl, aryl, heteroaryl, carboxyl, oxo, nitro, amino, alkylamino dialkylamino, carboxy, sulfonyl, sulfonamide, and cyano;
R12 is cycloalkyl, aryl or heteroaryl, optionally the aryl and heteroaryl is substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, hydroxyl, alkoxy, alkyl, cycloalkyl, carboxyl, oxo, nitro, amino, alkylamino dialkylamino, carboxy, sulfonyl, sulfonamide, and cyano;
R13 is —CH2—R15;
R14 is H, alkyl, alkenyl, alkynyl, or aryl, optionally the alkyl, alkenyl, alkynyl, and aryl is substituted with 1 or 2 substituents selected independently from the group consisting of halogen, hydroxyl, alkoxy, carboxyl, oxo, nitro, amino, alkylamino dialkylamino, carboxy, sulfonyl, sulfonamide, thiol, and cyan; and
R15 is alkyl, alkenyl, alkynyl, aryl, a nucleophile, optionally the alkyl, alkenyl, alkynyl and aryl is substituted with 1 or 2 substituents selected independently from the group consisting of halogen, hydroxyl, alkoxy, carboxyl, oxo, nitro, haloalkyl, aryl, heteroaryl, cycloalkyl, amino, alkylamino dialkylamino, carboxy, sulfonyl, sulfonamide, and cyano; and
a pharmaceutically acceptable salt thereof.